{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:36:48Z","timestamp":1787960208324,"version":"build-2784847793"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.kint.2022.09.023","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T18:55:54Z","timestamp":1666896954000},"page":"403-410","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Effects of aspirin on cardiovascular outcomes in patients with chronic kidney disease"],"prefix":"10.1016","volume":"103","author":[{"given":"Johannes F.E.","family":"Mann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prem","family":"Pais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Tyrwhitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Xavier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Dans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio Lopez","family":"Jaramillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habib","family":"Gamra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Yusuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2022.09.023_bib1","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.09.023_bib2","doi-asserted-by":"crossref","first-page":"629","DOI":"10.7326\/0003-4819-134-8-200104170-00007","article-title":"Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial","volume":"134","author":"Mann","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kint.2022.09.023_bib3","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1681\/ASN.2014070714","article-title":"Cause of death in patients with reduced kidney function","volume":"26","author":"Thompson","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2022.09.023_bib4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2215\/CJN.04100321","article-title":"Platelet abnormalities in CKD and their implications for antiplatelet therapy","volume":"17","author":"Baaten","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2022.09.023_bib5","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0140-6736(88)92019-3","article-title":"Bleeding in renal failure","volume":"1","author":"Remuzzi","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2022.09.023_bib6","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1161\/CIR.0b013e318235eb4d","article-title":"AHA\/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation","volume":"124","author":"Smith","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2022.09.023_bib7","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2022.09.023_bib8","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.09.023_bib9","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1056\/NEJMoa1800722","article-title":"Effect of aspirin on disability-free survival in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.09.023_bib10","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","article-title":"Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial","volume":"392","author":"Gaziano","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2022.09.023_bib11","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMe1812000","article-title":"Should aspirin be used for primary prevention in the post-statin era?","volume":"379","author":"Ridker","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.09.023_bib12","article-title":"Primary care providers should prescribe aspirin to prevent cardiovascular disease based on benefit-risk ratio, not age","volume":"9","author":"Kim","year":"2021","journal-title":"Fam Med Community Health"},{"key":"10.1016\/j.kint.2022.09.023_bib13","doi-asserted-by":"crossref","first-page":"445","DOI":"10.7326\/0003-4819-156-6-201203200-00007","article-title":"Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis","volume":"156","author":"Palmer","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kint.2022.09.023_bib14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.atherosclerosis.2016.06.013","article-title":"Aspirin and cardiovascular primary prevention in non-endstage chronic kidney disease: a meta-analysis","volume":"251","author":"Major","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.kint.2022.09.023_bib15","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jacc.2010.02.068","article-title":"Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial","volume":"56","author":"Jardine","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.kint.2022.09.023_bib16","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.kint.2020.08.011","article-title":"Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease","volume":"99","author":"Wolfe","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2022.09.023_bib17","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa2028220","article-title":"Polypill with or without aspirin in persons without cardiovascular disease","volume":"384","author":"Yusuf","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.09.023_bib18","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/j.ajkd.2004.11.015","article-title":"First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease","volume":"45","author":"Baigent","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2022.09.023_bib19","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMra054415","article-title":"Assessing kidney function\u2014measured and estimated glomerular filtration rate","volume":"354","author":"Stevens","year":"2006","journal-title":"N\u00a0Engl J Med"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253822008481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253822008481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T10:55:07Z","timestamp":1732791307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253822008481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0085253822008481"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2022.09.023","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of aspirin on cardiovascular outcomes in patients with chronic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2022.09.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2022.10.018","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}